Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Clinical trial NCT06472245 · RECRUITING
Trial details
- NCT number
- NCT06472245
- Sponsor
- OSE Immunotherapeutics
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-03
- Primary completion
- 2027-12-15
- Enrollment
- 363
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.